Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis

British Journal of Clinical Pharmacology

Volumn 59, Issue 3, 2005, Pages 291-297

  Hui, C K ^a   Cheung, B M Y ^a,b   Lau, G K K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; Cirrhosis; Liver; Pharmacokinetics; Pitavastatin; Statin

Indexed keywords

LACTONE; PITAVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; HUMAN; LIVER CIRRHOSIS; MALE; MAXIMUM ALLOWABLE CONCENTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADULT; AREA UNDER CURVE; ENZYME INHIBITORS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; QUINOLINES; TIME FACTORS;

EID: 15244362340     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02251.x     Document Type: Article

References (17)

1. Consensus conference. Lowering blood cholesterol to prevent heart disease. JAMA 1985; 253: 2080-6.
2. Anderson KM, Castelli WP, Levy D, Cholesterol, mortality. 30 years of follow-up from the Framingham study. JAMA 1987; 257: 2176-80.
3. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dysupidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
4. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med 1995; 332: 1491-8.
5. The West Scotland Coronary Prevention Study Group A coronary primary prevention study of Scottish men aged 45-64 years: trial design. J Clin Epidemiol 1992; 45: 849-60.
6. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383-9.
7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. for West Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301-7.
8. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3- methylglutaryl-coenzyme A reductase. Arzneimittelforschung 1997; 47: 904-9.
9. Saito Y, Yamada N, Teramoto T, ltakura H, Hata Y, Nakaya N, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolaemia. Atherosclerosis 2002; 162: 373-9.
10. Pan HY. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol 1991; 40(Suppl 1): S15-8.
11. Deslypere JP. Clinical Implications of the Biopharmaceutical Properties of Fluvastatin. Am J Cardiol 1994; 73: 12D-17D.
12. Gibson DM, Yang BB, Abel RB, Blum RA, Horton M, Stern RH, Sedman AJ, Whitfield LR. Effects of hepatic and renal impairment on pharmacokinetics (PK) and pharmacodynamics (PD) of atorvastatin. Pharm Res 1996; 13(Suppl 9): S428.
13. Fujino H, Yamada I, Kojima J, Hirano M, Katsumoto H, Yoneda M. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human. Xenobio Metabol Dispos 1999; 14: 415-24.
14. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 2001; 297: 861-7.
15. Mori H, Yamada M, Kataumi S, Mori M, Saito Y. Pharmacokinetics of Pitavastatin (NK-104) Administered for 7-days to Volunteers with Fatty Liver -Pharmacokinetics and Safety of Pitavastatin Administered 2 mg Daily for 7 days to 12 Volunteers, 6 with Fatty Liver, 6 Normal. Rinsho Iyaku 2003; 19: 371-9.
16. Kojima J, Fujino H, Yosimura M, Morikawa H, Kimata H. Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1999; 724: 173-80.
17. Nakaya N, Tateno M, Nakamura T, Kojima J. Pharmacokinetics of Repeated Dose NK-104 (Pitavastatin) in Healthy Elderly and Non-elderly Volunteers. Rinsho Iyaku 2001; 17: 957-70.